Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
LI_182741 | Pages: NA | Charts: NA | Tables: NA |
Platelet rich plasma (PRP) is derived from blood. It is produced when the human blood is spun down and platelet rich plasma is separated that have a concentration of platelets above the normal values. Platelets help in blood clotting as well as enhance the healing of tendons, muscles, and ligaments. PRP is used in different surgeries such as augmentation of shoulder rotator cuff and tendon repair.
Platelets are extremely rich in healing factors and connective tissue growth.
The major factors that enhance the market growth are growth in geriatric population, increase in incidence of sports and orthopedic injuries, rise in number of cosmetic surgical procedures, technological advancements, and increase in awareness regarding PRP therapies. However, difficulty in quality control of test results, thereby restrain the market growth.
The market is segmented based on product, origin, application, and geography. By product, this market is categorized into pure PRP, leukocyte rich PRP, and leukocyte rich fibrin. By origin, it is classified into autologous PRP, allogeneic PRP, and homologous PRP. By application, it is divided into orthopedic surgery, cosmetic surgery, general surgery, neurosurgery, and others. By geography, it is studied across North America, Europe, Asia Pacific, and LAMEA.
Key Benefits
List of players profiled in the report
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
356.3. Opportunities
CHAPTER 4 PLATELET RICH PLASMA MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. PURE PRP
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. LEUKOCYTE RICH PRP
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. LEUKOCYTE RICH FIBRIN
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 PLATELET RICH PLASMA MARKET, BY ORIGIN
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. AUTOLOGOUS PRP
5.2.1. Market size and forecast
5.3. ALLOGENEIC PRP
5.3.1. Market size and forecast
5.4. HOMOLOGOUS PRP
5.3.1. Market size and forecast
CHAPTER 6 PLATELET RICH PLASMA MARKET, BY APPLICATION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. ORTHOPEDIC SURGERY
6.2.1. Market size and forecast
6.3. COSMETIC SURGERY
6.3.1. Market size and forecast
6.4. GENERAL SURGERY
6.4.1. Market size and forecast
6.5. NEUROSURGERY
6.5.1. Market size and forecast
6.6. OTHERS
6.6.1. Market size and forecast
CHAPTER 7 PLATELET RICH PLASMA MARKET, BY GEOGRAPHY
7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast
7.2.4. North America Platelet Rich Plasma Market by Product
7.2.5. North America Platelet Rich Plasma Market by Origin
7.2.6. North America Platelet Rich Plasma Market by Application
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast
7.3.4. Europe Platelet Rich Plasma Market by Product
7.3.5. Europe Platelet Rich Plasma Market by Origin
7.3.6. Europe Platelet Rich Plasma Market by Application
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Rest of Asia-Pacific market size and forecast
7.4.4. Asia-Pacific Platelet Rich Plasma Market by Product
7.4.5. Asia-Pacific Platelet Rich Plasma Market by Origin
7.4.6. Asia-Pacific Platelet Rich Plasma Market by Application
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.3.1. Latin America market size and forecast
7.5.3.2. Middle East market size and forecast
7.5.3.3. Africa market size and forecast
7.5.4. LAMEA Platelet Rich Plasma Market by Product
7.5.5. LAMEA Platelet Rich Plasma Market by Origin
7.5.6. LAMEA Platelet Rich Plasma Market by Application
CHAPTER 8 COMPANY PROFILES
8.1. ARTHREX, INC.
8.1.1. Operating business segments
8.1.3. Business performance
8.1.3. Key strategic moves and developments
8.3. ZIMMER BIOMET
8.3.1. Operating business segments
8.3.3. Business performance
8.3.3. Key strategic moves and developments
8.3. HARVEST TECHNOLOGIES CORPORATION
8.3.1. Operating business segments
8.3.3. Business performance
8.3.3. Key strategic moves and developments
8.4. DEPUY SYNTHES, INC.
8.4.1. Operating business segments
8.4.3. Business performance
8.4.3. Key strategic moves and developments
8.5. STRYKER CORPORATION
8.5.1. Operating business segments
8.5.3. Business performance
8.5.3. Key strategic moves and developments
8.6. ADISTEM LTD.
8.6.1. Operating business segments
8.6.3. Business performance
8.6.3. Key strategic moves and developments
8.7. ISTO BIOLOGICS
8.7.1. Operating business segments
8.7.3. Business performance
8.7.3. Key strategic moves and developments
8.8. CESCA THERAPEUTICS, INC.
8.8.1. Operating business segments
8.8.3. Business performance
8.8.3. Key strategic moves and developments
8.9. EXACTECH INC.
8.9.1. Operating business segments
8.9.3. Business performance
8.9.3. Key strategic moves and developments
8.10. NUO THERAPEUTICS
8.10.1. Operating business segments
8.10.3. Business performance
8.10.3. Key strategic moves and developments